Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Study to Investigate the Pharmacokinetics and Safety of Remibrutinib (LOU064) in Participants With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function

Next Previous
Search
Trial Profile

A Phase 1, Open-label, Study to Investigate the Pharmacokinetics and Safety of Remibrutinib (LOU064) in Participants With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remibrutinib (Primary)
  • Indications Asthma; Chronic urticaria; Hidradenitis suppurativa; Liver disorders; Multiple sclerosis; Peanut hypersensitivity; Sjogren's syndrome
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 25 Mar 2025 According to a Novartis Media Release, data from the study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego from April 5-9, 2025.
    • 26 Feb 2024 Status changed from recruiting to completed.
    • 23 Oct 2023 Parallel has been removed from design terms, interventional study model is now crossover.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top